Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Amylin Pharmaceuticals have reported that Exenatide can control blood sugar as effectively as NovoNordisk's NovoMix 30 for people with type 2 diabetes that are unable to achieve acceptable blood sugar control on metformin and a sulfonylurea, two common oral diabetes medications.
Subscribe to our email newsletter
During the one-year study, patients using Exenatide showed improvements in three important measures of blood glucose control: fasting blood glucose, postprandial blood glucose, and hemoglobin A1C (HbA1C). Exenatide treatment also resulted in an average reduction in body weight, the companies said.
The American Diabetes Association recommends a target HbA1C – a measure of a person's average blood glucose level over a three-month period – of less than 7%, which 32% of study participants achieved.
In addition, patients on Exenatide lost an average of 2.5 kilograms, while those receiving biphasic insulin aspart gained an average of 2.9 kilograms. Weight gain is a common side effect of insulin therapy.
Professor Michael Nauck, a lead author of the study, said: “These data show that Exenatide, without the inconvenience of dose titration, is a potential alternative to biphasic insulin aspart for the treatment of patients with type 2 diabetes not adequately treated with metformin and a sulfonylurea, commonly used oral antidiabetic agents.”
Exenatide is the first in a new class of medicines known as incretin mimetics and was approved for use in the United States by the FDA in April 2005 for the treatment of type 2 diabetes. Exenatide is injected twice daily. Lilly is awaiting approval for exenatide in the European Union.